Mirum Pharmaceuticals, Inc. (MIRM) Tops Q3 EPS by 15c ; Offers Guidance

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q3 EPS of ($0.30), $0.15 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $90.38 million versus the consensus estimate of $81.99 million.

GUIDANCE:

Mirum Pharmaceuticals, Inc. sees FY2024 revenue of $330-335 million, versus the consensus of $316.3 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Barclays Upgrades Schott Pharma AG (1SXP:GR) to Overweight
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24